U.S. markets open in 3 hours 49 minutes

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.05-0.25 (-1.63%)
At close: 4:00PM EST

15.00 -0.05 (-0.33%)
Pre-Market: 5:23AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close15.30
Open15.29
Bid0.00 x 3000
Ask0.00 x 1000
Day's Range14.85 - 15.38
52 Week Range12.75 - 19.24
Volume16,272,437
Avg. Volume11,933,951
Market Cap18.291B
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 27, 2007
1y Target Est20.73
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Viatris Stock Sacrifices A Breakout As 2021 Guidance Falls Short
    Investor's Business Daily

    Viatris Stock Sacrifices A Breakout As 2021 Guidance Falls Short

    Generic-drug maker Viatris initiated a dividend on Monday, but VTRS stock plummeted after the company issued a downbeat 2021 outlook. Viatris is a combination of Pfizer's Upjohn and Mylan.

  • MarketWatch

    Viatris stock tumbles to pace S&P 500 losers after downbeat revenue, free cash flow outlooks

    Shares of Viatris Inc. tumbled 11.0% in premarket trading, to pace all of the S&P 500's decliners ahead of the open, after the pharmaceutical and health care services company provided a downbeat 2021 revenue outlook, while saying it was initiating a dividend. The company, formed in November through the combination of Mylan and Pfizer Inc.'s Upjohn business, said it expects 2021 revenue of $17.2 billion to $17.8 billion, compared with the FactSet consensus of $18.36 billion. Free cash flow is expected to be $2.0 billion to $2.3 billion, below the FactSet consensus of $3.78 billion. "We are confident that our financial guidance for 2021 is the right starting point for Viatris and continue to expect 2021 to be our trough year in terms of revenue, adjusted EBITDA and free cash flow, reflecting a balanced view of both near-term tailwinds and headwinds, particularly given the delay in closing of the combination between Mylan and Pfizer's Upjohn business," said Viatris Chief Executive Michael Goettler. The company said it was initiating an annualized dividend of 44 cents a share, with the first quarterly dividend of 11 cents a share to be distributed in June.

  • Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments
    PR Newswire

    Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments

    Viatris Inc. (NASDAQ: VTRS) today announced its 2021 financial guidance and reaffirmed its commitment to rapid de-leveraging, to enhancing and growing free cash flows, particularly following the phasing out of one-time and other stand up costs, to initiating a dividend, and to delivering total shareholder return (TSR).